SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Hyperfine, Inc. (HYPR) News

Track canonical SquawkNews coverage tagged to HYPR, Hyperfine, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol HYPR Asset equity Sector Markets 90 days 6 Last 0.8335 Updated Sep 28, 2026, 12:15 PM UTC Open live news feed
L Hyperfine, Inc. (HYPR) Names Exclusive Distributor for Kuwait and UAE Hyperfine appointed Roots Pharmaceutical as exclusive distributor for its Swoop portable brain MRI in Kuwait and the UAE, covering market development, regulatory support, and, post-clearances, commercialization and servi NEWS | Sep 28, 2026, 12:15 PM UTC L Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the a REGULATION | Sep 28, 2026, 12:15 PM UTC L Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that REGULATION | Sep 15, 2026, 12:15 PM UTC L Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans EQUITY | Aug 26, 2026, 12:20 PM UTC L Hyperfine Affirms FY2026 Sales Guidance of $20.000M-$22.000M vs $20.163M Est Hyperfine (NASDAQ: HYPR ) affirms FY2026 sales outlook from $20.000 million-$22.000 million to $20.000 million-$22.000 million vs $20.163 million estimate. EARNINGS | Aug 06, 2026, 08:16 PM UTC M Hyperfine Releases Peer-Reviewed Publications Hyperfine expands clinical evidence for Swoop System EQUITY | Jul 30, 2026, 12:16 PM UTC L HYPR Forms Advisory Council HYPR Hyperfine forms global neurosurgery advisory council to support portable MRI expansion EQUITY | Jun 22, 2026, 12:17 PM UTC